Part I: General GI -- Chapter 1: Introduction -- Chapter 2: Eosinophilic esophagitis -- Chapter 3: Oropharyngeal dysphagia -- Chapter 4: Achalasia -- Chapter 5: Other motility disorders of the esophagus and achalasia -- Chapter 6: GERD -- Chapter 7: Refractory GERD -- Chapter 8: Surgery for GERD -- Chapter 9: Barrett's esophagus -- Chapter 10: PEG Tubes -- Chapter 11: Autoimmune metaplastic atrophic gastritis -- Chapter 12: Subepithelial lesions and NETs -- Chapter 13: Viewpoints on managing common clinical GI disorders from a practitioner with over 50 Years of "Real-World" experience -- Chapter 14: Small intestinal bacterial overgrowth -- Chapter 15: Unusual causes of abdominal pain and controversies in diagnosis -- Chapter 16: Vascular disorders of the intestine -- Chapter 17: Polypectomy -- Chapter 18: Rectal incontinence -- Chapter 19: Diverticulitis -- Chapter 20: Pancreatic cysts and recurrent pancreatitis -- Chapter 21: Chronic pancreatitis -- Chapter 22: GI oncology -- Chapter 23: Issues in therapeutic endoscopy -- Chapter 24: GI pharmacology -- Part II: IBD Compendium -- Chapter 25: Introduction -- Chapter 26: Crohn's ileitis -- Chapter 27: Ulcerative colitis refractory to mesalamine -- Chapter 28: Managing Crohn's in a patient with prior MI -- Chapter 29: Managing post-op Crohn's -- Chapter 30: Managing pseudopolyps -- Chapter 31: Ulcerative colitis refractory to anti-TNFs -- Chapter 32: Severe ulcerative colitis -- Chapter 33: Resistant/refractory proctitis -- Chapter 34: Vaccinations in newly diagnosed IBD -- Chapter 35: Ustekinumab vs risankizumab in Crohn's -- Chapter 36: Use of vedolizumab in UC -- Chapter 37: Functional diarrhea in IBD -- Chapter 38: When to postpone infusions -- Chapter 39: Musculoskeletal complaints in a patient on anti-TNFs -- Chapter 40: Use of immune modulators in patients being started on anti-TNFs.-Chapter 41: Pyoderma gangrenosum -- Chapter 42: UC in a patient who failed mesalamine and anti-TNF -- Chapter 43: Patients with IBD who are squeamish about rectal meds and self-injection -- Chapter 44: Colon stricture in UC -- Chapter 45: Nonspecific ileal ulcers -- Chapter 46: Concern about Pneumocystis jirovecii -- Chapter 47: Bloating in Crohn's -- Chapter 48: Severe diarrhea in a patient on chemotherapy -- Chapter 49: Microscopic colitis -- Chapter 50: Miscellaneous questions -- Part III: Disorders of the Gut-Brain Interaction -- Chapter 51: Introduction -- Chapter 52: IBS-D -- Chapter 53: IBS-C -- Chapter 54: Functional dyspepsia -- Chapter 55: Bloating -- Part IV: Hepatology Compendium -- Chapter 56: Introduction -- Chapter 57: Liver enzyme elevation-negative work-up -- Chapter 58: Increased LFTs with increased iron -- Chapter 59: Increased LFTs with low ceruloplasmin -- Chap^ALT -- Chapter 64: Marked hyperbilirubinemia -- Chapter 65: Suspected NAFLD -- Chapter 66: Treatment of NAFLD -- Chapter 67: Treatment of MASLD -- Chapter 68: Alcohol and liver disease in women -- Chapter 69: Alcoholic hepatitis -- Chapter 70: Fatty Liver on ultrasound with normal liver enzymes -- Chapter 71: Evaluation for liver damage from chronic alcohol use -- Chapter 72: Ascites in a patient without obvious cirrhosis -- Chapter 73: Ascites in a patient with cirrhosis of unclear etiology with increased mononuclear cells -- Chapter 74: Low SAAG ascites -- Chapter 75: Banding esophageal varices -- Chapter 76: Gastric varices -- Chapter 77: Increased ascites in a stable cirrhotic -- Chapter 78: Complications related to managing ascites -- Chapter 79: Portal vein thrombosis as a complication of cirrhosis -- Chapter 80: Portal vein thrombosis and Budd-Chiari in a patient with ulcerative colitis -- Chapter 81: HCC management, solitary lesion in a Child's A cirrhotic -- Chapter 82: Management of Unresectable HCC in a Cirrhotic -- Chapter 83: HCC in NAFLD without Cirrhosis -- Chapter 84: Managing primary biliary cholangitis -- Chapter 85: Advanced PBC -- Chapter 86: Autoimmune hepatitis -- Chapter 87: Autoimmune hepatitis -- Chapter 88: Primary sclerosing cholangitis -- Chapter 89: PBC-AIH overlap -- Chapter 90: Immune-tolerant chronic HBV -- Chapter 91: Immune-active chronic HBV -- Chapter 92: HBV treatment discontinuation -- Chapter 93: Differentiating acute HBV from an acute exacerbation of chronic HBV -- Chapter 94: Acute HBV and risk of HBV reactivation -- Chapter 95: Complicated HCV -- Chapter 96: Acute liver failure -- Chapter 97: Delayed presentation of Tylenol overdose -- Chapter 98: Candidates for liver transplant? -- Chapter 99: Frustrations with waiting for a liver transplant -- Chapter 100: Complications post liver transplant. .